Cancer

News

Novartis steals a march in CDK4/6 market with breast cancer ...

Novartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in metastatic breast cancer. The results of the MONALEESA-7 trial – reported

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J unveils early-stage prostate cancer data from Erleada at...

Johnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC) – and new data p

News

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certa

News

Dynavax cuts staff and cancer R&D, focuses on vaccine

US biotech Dynavax has announced staff cutbacks after deciding to focus on its vaccine business, while winding down its immune-oncology research.

News

Novartis shows off pipeline - including 25 potential blockbu...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

Views & Analysis

Adapting for success

The last two decades have seen often limited treatment options for cancers give way to therapies with increasingly complex and targeted mechanisms of action as understanding of the disease

Novartis steals a march in CDK4/6 market with breast cancer ...

J&J unveils early-stage prostate cancer data from Erleada at...

AZ/Merck & Co reveal data supporting PARP drug in prostate c...

Dynavax cuts staff and cancer R&D, focuses on vaccine

Novartis shows off pipeline - including 25 potential blockbu...

Adapting for success

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks